Switch theme
Sign up to access all valuation multiples
Darwin AG is a biotechnology company. It is engaged in the field of human genetics. The group also develops and sells personalized dietary supplements and cosmetics. Its brand includes Novodaily; Rootine and Genopedia.
2021
n/a
LTM Revenue n/a
LTM EBITDA n/a
-$20.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Darwin has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Darwin achieved revenue of $19.5M and an EBITDA of $9.3M.
Darwin expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Darwin valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $235M | $19.5M | XXX | XXX | XXX |
| Gross Profit | $59.7M | $138M | XXX | XXX | XXX |
| Gross Margin | 25% | 706% | XXX | XXX | XXX |
| EBITDA | $72.5M | $9.3M | XXX | XXX | XXX |
| EBITDA Margin | 31% | 48% | XXX | XXX | XXX |
| Net Profit | $20.8M | $48.4M | XXX | XXX | XXX |
| Net Margin | 9% | 248% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Darwin's stock price is EUR 29 (or $31).
Darwin has current market cap of EUR 87.0M (or $93.4M), and EV of -EUR 18.7M (or -$20.0M).
See Darwin trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$20.0M | $93.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Darwin has market cap of $93.4M and EV of -$20.0M.
Darwin's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Darwin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Darwin and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$20.0M | XXX | XXX | XXX |
| EV/Revenue | -1.0x | XXX | XXX | XXX |
| EV/EBITDA | -2.2x | XXX | XXX | XXX |
| P/E | 2190.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDarwin's NTM/LTM revenue growth is n/a
Darwin's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Darwin's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Darwin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Darwin and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -92% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 48% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -87% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 54% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Darwin acquired XXX companies to date.
Last acquisition by Darwin was XXXXXXXX, XXXXX XXXXX XXXXXX . Darwin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Darwin founded? | Darwin was founded in 2021. |
| Where is Darwin headquartered? | Darwin is headquartered in Germany. |
| Is Darwin publicy listed? | Yes, Darwin is a public company listed on MUN. |
| What is the stock symbol of Darwin? | Darwin trades under 7V0 ticker. |
| When did Darwin go public? | Darwin went public in 2021. |
| Who are competitors of Darwin? | Similar companies to Darwin include e.g. SynBiotic, Mega Lifesciences, Procter & Gamble Health, Abbott India. |
| What is the current market cap of Darwin? | Darwin's current market cap is $93.4M |
| What is the current revenue growth of Darwin? | Darwin revenue growth between 2023 and 2024 was -92%. |
| Is Darwin profitable? | Yes, Darwin is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
